Literature DB >> 19036849

PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells.

Keiichi Kono1, Yuji Kamijo, Kazuhiko Hora, Kyoko Takahashi, Makoto Higuchi, Kendo Kiyosawa, Hidekazu Shigematsu, Frank J Gonzalez, Toshifumi Aoyama.   

Abstract

The activated mesangial cell is an important therapeutic target for the control of glomerulonephritis. The peroxisome proliferator-activated receptor alpha (PPARalpha) has attracted considerable attention for its anti-inflammatory effects; however, its roles in the mesangial cells remain unknown. To determine the anti-inflammatory function of PPARalpha in mesangial cells, wild-type and Ppara-null cultured mesangial cells were exposed to lipopolysaccharide (LPS). LPS treatment caused enhanced proinflammatory responses in the Ppara-null cells compared with wild-type cells, as revealed by the induction of interleukin-6, enhanced cell proliferation, and the activation of the nuclear factor (NF)-kappaB signaling pathway. In wild-type cells resistant to inflammation, constitutive expression of PPARalpha was undetectable. However, LPS treatment induced the significant appearance and substantial activation of PPARalpha, which would attenuate the proinflammatory responses through its antagonizing effects on the NF-kappaB signaling pathway. The induction of PPARalpha was coincident with the appearance of alpha-smooth muscle actin, which might be associated with the phenotypic changes of mesangial cells. Moreover, another examination using LPS-injected wild-type mice demonstrated the appearance of PPARalpha-positive cells in glomeruli, suggesting in vivo correlation with PPARalpha induction. These results suggest that PPARalpha plays crucial roles in the attenuation of inflammatory response in activated mesangial cells. PPARalpha might be a novel therapeutic target against glomerular diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036849     DOI: 10.1152/ajprenal.00484.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  21 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

3.  The role of nuclear receptors in the kidney in obesity and metabolic syndrome.

Authors:  Claudia Tovar-Palacio; Nimbe Torres; Andrea Diaz-Villaseñor; Armando R Tovar
Journal:  Genes Nutr       Date:  2012-04-25       Impact factor: 5.523

4.  Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Authors:  Ryosuke Usui; Masaki Takahashi; Kosaku Nitta; Minako Koike
Journal:  CEN Case Rep       Date:  2016-03-04

5.  Remifentanil temporarily improves renal function in adult patients with chronic kidney disease undergoing orthopedic surgery.

Authors:  Takerou Terashi; Akihiko Takehara; Tamotsu Kuniyoshi; Akira Matsunaga; Kouichi Kawasaki; Yuuichi Kanmura
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

6.  Fenofibrate, a PPARα agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB.

Authors:  Nan Zuo; Xiaoyu Zheng; Hanzhe Liu; Xiaoli Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia-reperfusion.

Authors:  Edgars Liepinsh; Elina Skapare; Janis Kuka; Marina Makrecka; Helena Cirule; Edijs Vavers; Eduards Sevostjanovs; Solveiga Grinberga; Osvalds Pugovics; Maija Dambrova
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-26       Impact factor: 3.000

Review 8.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

9.  Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney.

Authors:  Fei Ma; Fan Lin; Chen Chen; Jennifer Cheng; Darryl C Zeldin; Yan Wang; Dao Wen Wang
Journal:  Mol Pharmacol       Date:  2013-05-31       Impact factor: 4.436

10.  Modulation peroxisome proliferators activated receptor alpha (PPAR alpha) and acyl coenzyme A: cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell.

Authors:  Javad Zavvar Reza; Mahmoud Doosti; Masoud Salehipour; Malehieh Packnejad; Majed Mojarrad; Mansour Heidari
Journal:  Lipids Health Dis       Date:  2009-09-02       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.